Mohamed Elsafy։ Rethinking Hemostatic Management in Glanzmann Thrombasthenia with Sutacimig
Mohamed Elsafy, Drug Safety and Pharmacovigilance Lead Physician, Global Safety Strategy and Governance at ClinRM LLC, shared a post on LinkedIn:
”Sutacimig represents a novel and potentially transformative approach in Glanzmann thrombasthenia, shifting the paradigm from reactive bleeding management to true prophylaxis.
By leveraging a bispecific mechanism to localize and stabilize endogenous Factor VIIa at the platelet surface, this strategy directly addresses the underlying hemostatic defect. Early data showing meaningful reductions in bleeding burden are encouraging, particularly in a setting with no established preventive options.
If sustained in later-stage studies, this could redefine the standard of care in rare platelet disorders.”
Stay updated with Hemostasis Today.
-
May 7, 2026, 16:53Patricio S. Espinosa: Anticoagulation Is Not an Absolute Contraindication to Amyloid Therapy
-
May 7, 2026, 16:34Arun V J: Give Blood and Be the Hero You Always Wanted to Be
-
May 7, 2026, 16:15August Bones: When Would You Consider Placing an Inferior Vena Cava Filter After a Pulmonary Embolism?
-
May 7, 2026, 15:58Stop Asking Doctors to Do More – Reimagining the Care Team – The US Oncology
-
May 7, 2026, 15:42Chokri Ben Lamine: CVC-Associated UE-DVT and Catheter Removal
-
May 7, 2026, 15:38Samwel Mikaye: Key Insights on Vitamin B12 Deficiency
-
May 7, 2026, 15:37Anika Islam: A ‘Normal’ Hemoglobin Doesn’t Mean Your Patient is Safe for Surgery
-
May 7, 2026, 15:36Ekomobong Sunday: If You are Pregnant and Always Tired, Read This
-
May 7, 2026, 15:35Osama Ramadan: Comprehensive Review – 75 UWorld Anemia and RBC Disorders Questions Solved